KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Buildings: 2010-2013

Historic Buildings for Biomarin Pharmaceutical (BMRN) over the last 2 years, with Dec 2013 value amounting to $159.1 million.

  • Biomarin Pharmaceutical's Buildings rose 9.97% to $159.1 million in Q4 2013 from the same period last year, while for Dec 2013 it was $159.1 million, marking a year-over-year increase of 9.97%. This contributed to the annual value of $159.1 million for FY2013, which is 9.97% up from last year.
  • Biomarin Pharmaceutical's Buildings amounted to $159.1 million in Q4 2013, which was up 3.01% from $154.5 million recorded in Q3 2013.
  • Over the past 5 years, Biomarin Pharmaceutical's Buildings peaked at $159.1 million during Q4 2013, and registered a low of $138.0 million during Q4 2010.
  • Over the past 3 years, Biomarin Pharmaceutical's median Buildings value was $144.7 million (recorded in 2012), while the average stood at $147.0 million.
  • Data for Biomarin Pharmaceutical's Buildings shows a peak YoY climbed of 9.97% (in 2013) over the last 5 years.
  • Over the past 4 years, Biomarin Pharmaceutical's Buildings (Quarterly) stood at $138.0 million in 2010, then grew by 2.51% to $141.5 million in 2011, then grew by 2.27% to $144.7 million in 2012, then grew by 9.97% to $159.1 million in 2013.
  • Its Buildings was $159.1 million in Q4 2013, compared to $154.5 million in Q3 2013 and $147.0 million in Q2 2013.